Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $8.39 Consensus Price Target from Analysts

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) have earned an average rating of “Hold” from the nine analysts that are presently covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $8.39.

A number of brokerages have recently weighed in on RVNC. StockNews.com assumed coverage on Revance Therapeutics in a report on Monday. They set a “hold” rating on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th.

Revance Therapeutics Stock Performance

Shares of NASDAQ:RVNC opened at $3.65 on Tuesday. Revance Therapeutics has a one year low of $2.30 and a one year high of $6.65. The stock has a fifty day moving average of $3.65 and a 200-day moving average of $3.76. The company has a market capitalization of $381.02 million, a PE ratio of -1.89 and a beta of 0.90.

Institutional Investors Weigh In On Revance Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Beryl Capital Management LLC bought a new position in Revance Therapeutics during the fourth quarter valued at about $18,042,000. Alliancebernstein L.P. raised its holdings in Revance Therapeutics by 7.3% in the 4th quarter. Alliancebernstein L.P. now owns 3,497,112 shares of the biopharmaceutical company’s stock worth $10,631,000 after acquiring an additional 236,641 shares during the period. Magnetar Financial LLC lifted its position in Revance Therapeutics by 2.2% during the 4th quarter. Magnetar Financial LLC now owns 2,556,345 shares of the biopharmaceutical company’s stock worth $7,771,000 after acquiring an additional 56,174 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Revance Therapeutics by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 2,297,582 shares of the biopharmaceutical company’s stock worth $6,986,000 after purchasing an additional 7,928 shares during the last quarter. Finally, Newtyn Management LLC acquired a new stake in Revance Therapeutics in the 4th quarter valued at approximately $5,502,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.